Modifications of Sunitinib-Loaded GB-102 Microparticles that Lengthen Drug Release: 9-Months Ocular Tolerability and PK in Rabbit Following IVT Dosing



Current Challenges

Current neovascular AMD (nAMD) therapies are suboptimal due to:

- Need for frequent intravitreal dosing (every 4-8 wks) Inability to target more than one disease pathway

Purpose

- We previously reported that GB-102 delivered pharmacologically active levels of sunitinib in retina/RPEchoroid for 6 months. The purpose of this study is: To develop a new longer-lasting formulation of GB-102 with the goal of safely delivering sunitinib for up to 12 months following a single intravitreal injection.
- To evaluate the ocular tolerability and pharmacokinetics of the new formulation.

Methods


- A new longer-lasting formulation was developed and characterized for drug loading (~10% by weight), size (~30 µm) and *in vitro* release kinetics.
- Drug-containing (1 mg sunitinib) or placebo (drugfree) microparticles were injected (0.05 mL) into the vitreous of pigmented rabbits using a 27G needle.
- Ocular examinations were performed 10 days after dosing and monthly thereafter for up to 9 months.
- Ocular and plasma levels of sunitinib were assessed at 3, 6 and 9 months.

Yang, Ming¹; Peterson, Ward¹; Yu, Yun¹; Kays, Joshua¹; Cardona, Delia¹; Culp, David²; Gilger, Brian C.³; McKenzie, David¹; Anonuevo, Abraham¹; Hoang, Bryan¹; Yu, Connie¹; Cleland, Jeffrey¹ ¹Graybug Vision, Inc., Redwood City, CA, USA; ²Powered Research, LLC, Research Triangle Park, NC, USA; ³Clinical Sciences, North Carolina State University, Raleigh, NC, USA





5 mm Form an



- release kinetics.
- retina/RPE-choroid for at least 9-months post-dose.
- nAMD.

Conclusions

IVT injection of the new GB-102 formulation is well-tolerated and able to maintain pharmacologically active levels in

• A single IVT injection of the new GB-102 microparticles may be able to retain active drug levels in retina/RPE-choroid up to 12 months due to reversible melanin-binding properties and potentially enable once-per-year treatment for

Ongoing formulation optimization work to further improve release kinetics.